CSPC Pharma Reports Steady Growth and Shareholder Rewards

CSPC Pharmaceutical Group (HK:1093) has released an update.

CSPC Pharmaceutical Group Limited reported a modest revenue increase of 1.3% and a slight profit growth, with underlying profit up by 1.7% and reported profit by 1.8% for the first half of 2024, compared to the previous year. The company has raised its interim dividend by 14.3% and is actively pursuing share buy-backs, reflecting confidence in its business prospects and aiming to enhance shareholder returns.

For further insights into HK:1093 stock, check out TipRanks’ Stock Analysis page.